Search Result

Results for "

α7nAChR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (1) Apoptosis (3) Bacterial (2) Cholinesterase (ChE) (2) Isotope-Labeled Compounds (3) JAK (1) nAChR (54) NO Synthase (1) Parasite (2) Potassium Channel (2) STAT (1)
By Research Areas:	Cancer (2) Infection (2) Inflammation/Immunology (8) Neurological Disease (51)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19490

VQW-765 AQW-051	nAChR	Neurological Disease
VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pK_D value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety .

HY-N2332A

Methyllycaconitine citrate Maximum Cited Publications 25 Publications Verification MLA	nAChR	Neurological Disease
Methyllycaconitine citrate is a specific antagonist of α7 neuronal nicotinic acetylcholine receptor (α7nAChR) with blood-brain barrier permeability.

HY-105670

PHA-543613	nAChR	Neurological Disease
PHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-14564A

GTS-21 dihydrochloride 5+ Cited Publications DMXB-A; DMBX-anabaseine	nAChR 5-HT Receptor	Inflammation/Immunology
GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor *(α7-nAChR)* agonist with anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also a α4β2 (K_i=20 nM for humanα4β2) and 5-HT3A receptor (IC₅₀=3.1 μM) antagonist .

HY-160529

*α7 nAChR* Modulator-2**	nAChR	Neurological Disease
α7 nAChR Modulator-2 (Compound 7b) is a α7 nAChR positive allosteric modulator (PAM) with an *EC₅₀ of 2.1 μM. α7 nAChR* Modulator-2 can be used for the research of cognitive disorders .**

HY-157958

*α7 nAChR* Modulator-3**	nAChR	Neurological Disease
α7 nAChR modulator-3 (Compound 6p) is a α7 nAChR positive allosteric Modulator with a IC₅₀ value of 1.3 μM. α7 nAChR Modulator-3 can be used to inhibit auditory gating defects in a mouse schizophrenic model .

HY-146066

*α7 nAchR-JAK2-STAT3 agonist 1*	nAChR JAK STAT NO Synthase	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-P5839

α-Conotoxin MrIC	nAChR	Neurological Disease
α-Conotoxin MrIC is an *α7nAChR* biased agonist. α-Conotoxin MrIC exclusively activates *α7nAChR* regulated by type II positive allosteric modulators, including PNU120596. α-Conotoxin MrIC can be used to study neurological diseases and also to probe the pharmacological properties of *α7nAChR* .

HY-105670B

PHA-543613 dihydrochloride	nAChR	Neurological Disease
PHA-543613 dihydrochloride is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i value of 8.8 nM. PHA-543613 dihydrochloride displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 dihydrochloride can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-14564

GTS-21	nAChR 5-HT Receptor	Inflammation/Immunology
GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor *(α7-nAChR)* agonist with anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also a α4β2 (K_i=20 nM for humanα4β2) and 5-HT3A receptor (IC₅₀=3.1 μM) antagonist. GTS-21 can be used in age-associated memory impairment (AAMI) and Alzheimer's disease research .

HY-12152

PNU-120596 1 Publications Verification NSC 216666	nAChR	Neurological Disease Inflammation/Immunology
PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) with an EC₅₀ of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research .

HY-12150

CCMI 1 Publications Verification AVL-3288; UCI-4083	nAChR	Neurological Disease
CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction .

HY-12151

NS 1738 NSC 213859	nAChR	Neurological Disease
NS 1738 (NSC 213859) is a novel positive allosteric modulator of the α7 nAChR, with respect to positive modulation of α7 nAChR (EC₅₀=3.4 μM in oocyte experiments).

HY-107672

MG624 Stilonium iodide	nAChR	Neurological Disease
MG624 is a potent and selective neuronal α7 nAChR antagonist with a K_i of 106 nM .

HY-107673

RJR-2429 dihydrochloride	nAChR	Neurological Disease
RJR 2429 hydrochloride is a α4β2 and α7 nAChR agonist .

HY-117611

GAT107	nAChR	Neurological Disease
GAT107 (compound 1b) is a potent α7 nAChR ago-PAMs (positive allosteric modulators) .

HY-114269

(-)-(S)-B-973B	nAChR	Neurological Disease
(-)-(S)-B-973B is a potent allosteric agonist and positive allosteric modulator of α7 nAChR, with antinociceptive activity .

HY-11053

S 24795	nAChR	Neurological Disease
S 24795 is a partial agonist of α7 nAChR and improves mnemonic function in aged mice for the research of aging-related memory disturbances .

HY-107678

SEN12333 WAY-317538	nAChR	Neurological Disease
SEN 12333 (WAY-317538) is a potent, selective and orally active α7 nAChR agonist. SEN12333 displays high affinity for the rat α7 nAChRs expressed in GH4C1 cells (K_>i=260 nM) and acts as full agonist in functional Ca ²⁺ flux studies (EC₅₀=1.6 μM). SEN 12333 is used for AD and schizophrenia research .

HY-10814

CP-810123	nAChR	Neurological Disease
CP-810123 is a brain-permeable agonist of α7 nAChR for the research of cognitive impairment associated with psychiatric or neurological disorders such as schizophrenia and Alzheimer's disease .

HY-19411

SSR180711 hydrochloride	nAChR	Neurological Disease
SSR180711 hydrochloride is an orally active, selective and reversible α7 acetylcholine nicotinic receptor (n-AChRs) partial agonist. SSR180711 hydrochloride can act on rat α7 n-AChR (K_i=22 nM; IC₅₀=30 nM) and human α7 n-AChR (K_i=14 nM; IC₅₀=18 nM). SSR180711 hydrochloride increases glutamatergic neurotransmission, ACh release and long-term potentiation (LTP) in the hippocampus .

HY-110087

4BP-TQS	nAChR	Neurological Disease
4BP-TQS is a potent allosteric agonist of α7 *nAChR. 4BP-TQS activates nAChRs* via an allosteric transmembrane site .

HY-P1267

α-Conotoxin PnIA	nAChR	Neurological Disease
α-Conotoxin PnIA, a potent and selective antagonist of the mammalian α7 nAChR, has the potential for the research of neurological conditions such as neuropathic pain and Alzheimer’s disease .

HY-P1267A

α-Conotoxin PnIA TFA	nAChR	Neurological Disease
α-Conotoxin PnIA TFA, a potent and selective antagonist of the mammalian α7 nAChR, has the potential for the research of neurological conditions such as neuropathic pain and Alzheimer’s disease .

HY-133011

nAChR agonist 1	nAChR	Neurological Disease
nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC₅₀ of 0.32 µM in a Ca ²⁺ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .

HY-12560D

PNU-282987 S enantiomer free base	nAChR	Others
PNU-282987 S enantiomer free base is the S-enantiomer of PNU-282987 free base. PNU-282987 is an α7 nicotinic acetylcholine receptor (α7 nAChR) agonist.

HY-B1178A

R-(+)-Cotinine (+)-Cotinine; (R)-Cotinine; (R)-NIH-10498	nAChR	Neurological Disease
R-(+)-Cotinine ((+)-Cotinine), a Nicotine metabolite, lacks significant activity across a wide range of pharmacological targets. R-(+)-Cotinine can enhance the Ach-evoked current in human α7 nAChRs .

HY-129674

PHA 568487 free base	nAChR	Neurological Disease
PHA 568487 free base is a selective alpha 7 nicotinic acetylcholine receptor (α-7 nAchR) agonist. PHA 568487 free base reduces neuroinflammation .

HY-107683

LY-2087101	nAChR	Neurological Disease
LY-2087101 is an allosteric potentiator of α7 nAChRs. LY-2087101 causes potentiation of agonist-evoked α7 responses by binding within the nAChR transmembrane region .

HY-116507

AZD0328	nAChR	Neurological Disease
AZD0328 is a selective α7 nAChR partial agonist. AZD0328 selectively enhances midbrain dopaminergic neuronal activity and enhances cortical dopamine levels in rats. AZD0328 improves cognitive performance .

HY-18060

Bradanicline TC-5619	nAChR	Neurological Disease
Bradanicline is a highly selective α7 nicotinic acetylcholine receptor (nAChR) agonist (humanα7 nAChR: EC₅₀=17 nM; K_i= 1.4 nM). Bradanicline is used for the research of cognitive disorders .

HY-146405

nAChR antagonist 1	nAChR	Neurological Disease Inflammation/Immunology
nAChR antagonist 1 (compound B15) is an excellent α7 nAChR antagonist with an IC₅₀ value of 3.3 μM. nAChR antagonist 1 can be used for researching schizophrenia, Alzheimer’s disease and inflammatory disorders .

HY-128575

BNC375	nAChR	Neurological Disease
BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC₅₀ of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. .

HY-16748

Nelonicline ABT-126	nAChR	Neurological Disease
Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease .

HY-B0567

Dequalinium Chloride	Potassium Channel nAChR Apoptosis Bacterial Parasite	Infection Cancer
Dequalinium chloride is an Apamin (HY-P0256)-sensitive potassium channel selective blocker. Dequalinium chloride is a cationic, lipophilic mitochondrial poison. Dequalinium chloride is also an antagonist pf α7 nAChR, and an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity .

HY-106901A

Asoxime dichloride HI-6	nAChR	Neurological Disease
Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system .

HY-16748A

Nelonicline citrate ABT-126 citrate	nAChR	Neurological Disease
Nelonicline (ABT-126) citrate is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline citrate is used for the research of shizophrenia and Alzheimer's disease .

HY-107666

PHA 568487	nAChR	Neurological Disease Inflammation/Immunology
PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR) .PHA 568487 reduces neuroinflammation and oxidative stress . PHA-568487 has rapid brain penetration .

HY-18039

WAY-361789 SEN15924	Cholinesterase (ChE)	Neurological Disease
WAY-361789 (SEN15924) is an orally active agonist for α7 nicotinic acetylcholine receptor (α7 nAChR) with an EC₅₀ of 0.18 μM. WAY-361789 improves the cognitive function, exhibits potential in ameliorating Alzheimer’s Disease and schizophrenia .

HY-18060A

Bradanicline hydrochloride TC-5619 hydrochloride	nAChR	Neurological Disease
Bradanicline hydrochloride (TC-5619 hydrochloride) is the hydrochloride salt form of Bradanicline (HY-18060). Bradanicline hydrochloride is a selective agonist for α7 nicotinic acetylcholine receptor (nAChR), with EC₅₀ of 17 nM for human α7 nAChR and K_i of 1.4 nM. Bradanicline hydrochloride is used for the research of cognitive disorders and schizophrenia .

HY-105858

BNC210 H-Ile-Trp-OH; IW-2143	nAChR	Neurological Disease
BNC210 (H-Ile-Trp-OH) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. BNC210 exhibits acute anxiolytic activity in rodent models of anxiety. BNC210 can be used in studies of generalised anxiety disorders .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

HY-149776

RGH-560	nAChR	Neurological Disease
RGH-560 (compound 53) shows highly advanced α7 nAChR positive modulator properties and favorable physicochemical features. RGH-560 has robust procognitive in vivo potential. RGH-560 can be used to study Scopolamine (HY-N0296) -induced amnesia in mice .

HY-114791

Lobelanidine	nAChR	Neurological Disease
Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC₅₀ of 2.8 and 8.2 μM .

HY-106901AS

Asoxime-d4 dichloride HI-6-d₄	Isotope-Labeled Compounds nAChR	Neurological Disease
Asoxime-d₄ (dichloride) is the deuterium labeled Asoxime dichloride. Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system[1].

HY-105670A

PHA-543613 hydrochloride	nAChR	Neurological Disease
PHA-543613 hydrochloride is an oral or active α7 nAChR agonist with brain permeability, For α3β4, α1β1γδ, α4β2 and 5-HT3 receptors selective. PHA-543613 hydrochloride affects sensory gating and memory in an in vivo model of schizophrenia .

HY-B0567R

Dequalinium Chloride (Standard)	Potassium Channel nAChR Apoptosis Bacterial Parasite	Infection Cancer
Dequalinium (Chloride) (Standard) is the analytical standard of Dequalinium (Chloride). This product is intended for research and analytical applications. Dequalinium chloride is an Apamin (HY-P0256)-sensitive potassium channel selective blocker. Dequalinium chloride is a cationic, lipophilic mitochondrial poison. Dequalinium chloride is also an antagonist pf α7 nAChR, and an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity .

HY-137231B

(S)-UFR2709 hydrochloride	nAChR	Neurological Disease
(S)-UFR2709 (hydrochloride) is a competitive *nAChR* antagonist and displays higher affinity for α₄β₂ nAChRs than for α₇ nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 (hydrochloride) acts as an anxiolytic agent and can be used for the study of nicotine addiction .

HY-137231A

(S)-UFR2709	nAChR	Neurological Disease
(S)-UFR2709 is a competitive *nAChR* antagonist and displays higher affinity for α₄β₂ nAChRs than for α₇ nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 acts as an anxiolytic agent and can be used for the study of nicotine addiction .

HY-110160

Pozanicline dihydrochloride ABT-089 dihydrochloride	nAChR	Neurological Disease
Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a K_i of 16.7 nM for binding to [ ³H]cytisine sites . Pozanicline is an α4β2-selective *nAChR* agonist, which binds to rat brain α4β2 nAChR with a K_i of 17 nM while binding to α7 nAChR is insignificant .

Cat. No.	Product Name	Target	Research Area

HY-P1267A

α-Conotoxin PnIA TFA	nAChR	Neurological Disease
α-Conotoxin PnIA TFA, a potent and selective antagonist of the mammalian α7 nAChR, has the potential for the research of neurological conditions such as neuropathic pain and Alzheimer’s disease .

HY-P5839

α-Conotoxin MrIC	nAChR	Neurological Disease
α-Conotoxin MrIC is an *α7nAChR* biased agonist. α-Conotoxin MrIC exclusively activates *α7nAChR* regulated by type II positive allosteric modulators, including PNU120596. α-Conotoxin MrIC can be used to study neurological diseases and also to probe the pharmacological properties of *α7nAChR* .

HY-P1267

α-Conotoxin PnIA	nAChR	Neurological Disease
α-Conotoxin PnIA, a potent and selective antagonist of the mammalian α7 nAChR, has the potential for the research of neurological conditions such as neuropathic pain and Alzheimer’s disease .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-114791

Lobelanidine	Structural Classification Alkaloids Lobelia tupa L. Other Alkaloids Source classification Campanulaceae Plants	nAChR
Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC₅₀ of 2.8 and 8.2 μM .

HY-N0584B

Anisodamine hydrochloride 6-Hydroxyhyoscyamine hydrochloride	Structural Classification Alkaloids Pyrrole Alkaloids Anisodus tanguticus (Maxinowicz) Pascher Source classification Plants Solanaceae	Adrenergic Receptor
Anisodamine hydrochloride is an anticholinergic and α1 adrenergic receptor antagonist. Anisodamine hydrochloride can be used for improving blood flow in circulatory disorders such as septic shock, Anisodamine hydrochloride displays a spectrum of pharmacological effects similar to Atropine (HY-B1205) and Sopolamine (HY-B2065) including inhibition of salivation, gastrointestinal and sweat secretion, gastrointestinal motility, respiratory secretion and urinary bladder contraction in vivo .

Cat. No.	Product Name	Chemical Structure

HY-106901AS

Asoxime-d4 dichloride
Asoxime-d₄ (dichloride) is the deuterium labeled Asoxime dichloride. Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system[1].

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively[1]. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks